Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day’s gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassa...
Summary Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and resu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That’s because the Securities and Exchange Commission (SEC) has closed its case on...
Summary Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%. Cassava Sciences is looking to produce what will one day potentially be the best-selling drug of all time. ...
Summary The second group of patients on simufilam on average experienced a .2 point decline in ADAS-Cog scores after one year. These results are similar to acetylcholinesterase inhibitors for mild Alzheimer's disease. Critics claim that some individuals in the first group who ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: JHVEPhoto / Shutterstock.com General Mills (NYSE: GIS ) stock is getting a boost on Wednesday after the food company increased its full-year guidance for fiscal 2023 . That updated guidance has Genera...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sharaf Maksumov / Shutterstock.com Stitch Fix (NASDAQ: SFIX ) stock is taking a beating on Wednesday after the company released results for its fiscal fourth quarter of 2022 . The bad news for SFIX st...
The Cassava Sciences stock ( NASDAQ: SAVA ) has been very bullish over the past month. It has gained more than 58% in a span of 30 days and investors are still bullish on the stock. Yesterday, a whale with a lot of money to spend took a noticeably bullish stance on the SAVA st...
After a sharp selloff early this year, clinical-stage biotech Cassava Sciences ( NASDAQ: SAVA ) appears to be turning the tide, with its shares rising for the fourth straight session Friday on above-average volume to reach the highest level since April. Nearly 2.9M SAVA sh...
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global Inve...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...